Literature DB >> 19965877

Oral administration of the cyclooxygenase-2 (COX-2) inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception.

Kim E Hester1, Michael J K Harper, Diane M Duffy.   

Abstract

BACKGROUND: Prostaglandins produced via cyclooxygenase-2 (COX-2) within the periovulatory follicle are required for successful ovulation. Inhibition of follicular prostaglandin synthesis prevents timely follicle rupture and oocyte release. This study was conducted to determine if a 5-day course of oral administration of the COX-2 inhibitor meloxicam can prevent ovulation while maintaining normal menstrual cycles in non-human primates.
METHODS: Adult female cynomolgus monkeys were studied in each of four sequential menstrual cycles. In Cycle 1, a serum sample was obtained each day and assayed for estradiol, progesterone and luteinizing hormone; first menses was also noted to establish parameters of a normal menstrual cycle for each animal. In Cycle 2, meloxicam was administered orally once each day for 5 days beginning at either mid follicular (n = 4), late follicular (n = 4) or periovulatory (n = 4) phase of the menstrual cycle; daily serum samples and menses were assessed as for Cycle 1. In Cycle 3, the follicle-bearing ovary was removed 2 days after the expected day of ovulation (n = 3-4/treatment group). In Cycle 4, monkeys received the 5-day courses of oral meloxicam as in Cycle 2 (n = 3-4/treatment group), and the remaining ovary was removed. Ovaries were examined for the presence of an oocyte within the follicle.
RESULTS: Monkeys had the expected levels of changing reproductive hormones during Cycle 1. Meloxicam treatment in Cycle 2 did not alter hormone levels or the luteal phase length. Follicles of ovaries removed during Cycle 3 did not contain oocytes, indicating successful ovulation. Follicles did contain oocytes after meloxicam treatment beginning in the mid follicular (67%), late follicular (100%) or periovulatory (50%) phase of Cycle 4, indicating failure of ovulation.
CONCLUSIONS: A 5-day course of oral meloxicam administered around the time of ovulation reduced the rate of oocyte release without alteration of reproductive hormones or menstrual cycle length. Meloxicam may be effective as an emergency contraceptive in women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19965877     DOI: 10.1093/humrep/dep424

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  19 in total

1.  Prostaglandin E2 receptors are differentially expressed in subpopulations of granulosa cells from primate periovulatory follicles.

Authors:  Siabhon M Harris; Lindsey C Aschenbach; Stephanie M Skinner; Brandy L Dozier; Diane M Duffy
Journal:  Biol Reprod       Date:  2011-07-13       Impact factor: 4.285

2.  Pharmacokinetics of 3 formulations of meloxicam in cynomolgus macaques (Macaca fascicularis).

Authors:  Cassondra Bauer; Patrice Frost; Stephen Kirschner
Journal:  J Am Assoc Lab Anim Sci       Date:  2014-09       Impact factor: 1.232

3.  Prostaglandin E2 (EP) receptors mediate PGE2-specific events in ovulation and luteinization within primate ovarian follicles.

Authors:  Soon Ok Kim; Siabhon M Harris; Diane M Duffy
Journal:  Endocrinology       Date:  2014-02-07       Impact factor: 4.736

4.  Maturation and fertilization of nonhuman primate oocytes are compromised by oral administration of a cyclooxygenase-2 inhibitor.

Authors:  Diane M Duffy; Catherine A VandeVoort
Journal:  Fertil Steril       Date:  2011-01-14       Impact factor: 7.329

Review 5.  Ovulation: Parallels With Inflammatory Processes.

Authors:  Diane M Duffy; CheMyong Ko; Misung Jo; Mats Brannstrom; Thomas E Curry
Journal:  Endocr Rev       Date:  2019-04-01       Impact factor: 19.871

Review 6.  Novel contraceptive targets to inhibit ovulation: the prostaglandin E2 pathway.

Authors:  Diane M Duffy
Journal:  Hum Reprod Update       Date:  2015-05-29       Impact factor: 15.610

7.  Impact of the prostaglandin synthase-2 inhibitor celecoxib on ovulation and luteal events in women.

Authors:  Alison B Edelman; Jeffrey T Jensen; Carmen Doom; Jon D Hennebold
Journal:  Contraception       Date:  2012-08-16       Impact factor: 3.375

8.  Incessant ovulation and ovarian cancer - a hypothesis re-visited.

Authors:  M F Fathalla
Journal:  Facts Views Vis Obgyn       Date:  2013

9.  Metformin decreases the incidence of ovarian hyperstimulation syndrome: an experimental study.

Authors:  Evelin M Elia; Ramiro Quintana; Carlos Carrere; María V Bazzano; Gastón Rey-Valzacchi; Dante A Paz; María C Pustovrh
Journal:  J Ovarian Res       Date:  2013-09-08       Impact factor: 4.234

10.  Proteomic analysis of human follicular fluid from fertile women.

Authors:  Alberuni M Zamah; Maria E Hassis; Matthew E Albertolle; Katherine E Williams
Journal:  Clin Proteomics       Date:  2015-03-03       Impact factor: 3.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.